Updated NETs Clinical Trials

• Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases

  Conditions: Neuroendocrine Tumors Interventions: Procedure: Liver Transplantation Sponsors: Chiyi Chen Enrolling by invitation

• TRINITY TRIAL; Trial Of PRRT Plus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETS

  Conditions: Gastroenteropancreatic Neuroendocrine Tumors Interventions: Drug: Capecitabine; Drug: Temozolomide (TMZ); Drug: Lutetium Lu 177 Dotatate Sponsors: Tata Memorial Hospital; Tata Memorial Centre Not yet recruiting

• Immunotherapy in Neuroendocrine Carcinoma of the Cervix

  Conditions: Cervical Neuroendocrine Carcinoma Interventions: Other: No study intervention; observational study. Sponsors: Peking Union Medical College Hospital Not yet recruiting

• Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL)

  Conditions: Pheochromocytoma and Paraganglioma (PPGL) Interventions: Drug: Belzutifan Sponsors: Longfei Liu，MD Recruiting

• Multicenter Study for External Validation of the TB-NET Score

  Conditions: Tumor Burden; Neuroendocrine (NE) Tumors Sponsors: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz; University of Lausanne Hospitals; Dana-Farber Cancer Institute; Royal North Shore Hospital; Hacettepe University; UMC Utrecht; Instituto Alexander Fleming; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Hospital Universitario Marqués de Valdecilla; University Hospital in Krakow; Royal Free Hospital NHS Foundation Trust; Skane University Hospital; Royal Marsden NHS Foundation Trust; Uppsala University Hospital; Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen; Beaujon Hospital; Washington University School of Medicine; Hospital Sirio-Libanes; Ospedale San Raffaele Recruiting

• Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases

  Conditions: Gastroenteropancreatic Neuroendocrine Tumors Sponsors: First Affiliated Hospital of Fujian Medical University Recruiting

• QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

  Conditions: Extrapulmonary Neuroendocrine Carcinoma Interventions: Drug: Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen); Drug: QLC5508 Sponsors: Qilu Pharmaceutical Co., Ltd. Not yet recruiting

• Oxaliplatin-Based Adjuvant Therapy for Gastrointestinal Neuroendocrine Carcinoma**

  Conditions: Gastrointestinal Neuroendocrine Carcinoma; Adjuvant Treatment; Resection Sponsors: Peking Union Medical College Hospital Enrolling by invitation

• Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)

  Conditions: Well-Differentiated Neuroendocrine Tumors (NETs) Interventions: Other: PRO-CSS questionnaire Sponsors: Hospices Civils de Lyon; IPSEN PHARMA S.A.S; ENDOCAN RENATEN network Not yet recruiting

• A Phase 1 Study of IM-1340 in Participants With Advanced Cancer

  Conditions: Colorectal Cancer; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Neuroendocrine Neoplasm Interventions: Drug: IM-1340 Sponsors: Immunome, Inc. Not yet recruiting

• RET-Targeted Molecular Imaging Probes in Prostate Cancer

  Conditions: Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation; Prostate Cancer Interventions: Diagnostic Test: RET-targeted PET/CT molecular imaging; Diagnostic Test: PSMA-targeted PET/CT imaging Sponsors: Xiangya Hospital of Central South University Active, not recruiting

• Acupuncture for Symptom Burden and Quality of Life in Patients With End-Stage Kidney Disease

  Conditions: End Stage Kidney Disease (ESKD) Interventions: Other: Acupuncture; Other: Sham Acupuncture Sponsors: University General Hospital of Heraklion Not yet recruiting

• Dietary Education Intervention for Subthreshold Depression (MIND-Trial)

  Conditions: Subthreshold Depression Interventions: Behavioral: Mediterranean-Style Dietary Education Program; Behavioral: Befriending Sponsors: Institute of Mental Health, Singapore; Nanyang Technological University Not yet recruiting

• Multi-omics Study of Cervical Neuroendocrine Carcinoma

  Conditions: Cervical Neuroendocrine Carcinoma Interventions: Other: Multi-omics profiling of archived tumor tissue (observational) Sponsors: Peking Union Medical College Hospital Not yet recruiting

• Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma

  Conditions: Metastatic Differentiated Thyroid Gland Carcinoma; Metastatic NUT Carcinoma; Metastatic Thyroid Gland Anaplastic Carcinoma; Metastatic Thyroid Gland Medullary Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v8; Stage III Thyroid Gland Medullary Carcinoma AJCC v8; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IV Thyroid Gland Medullary Carcinoma AJCC v8; Unresectable Differentiated Thyroid Gland Carcinoma; Unresectable NUT Carcinoma; Unresectable Thyroid Gland Anaplastic Carcinoma; Unresectable Thyroid Gland Medullary Carcinoma Interventions: Procedure: Biopsy Procedure; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Enfortumab Vedotin; Procedure: Magnetic Resonance Imaging; Other: Survey Administration; Procedure: X-Ray Imaging Sponsors: Northwestern University; National Cancer Institute (NCI) Not yet recruiting

• The Impact of Long-term Isolation in Antarctica on Social Touch and Its Underlying Biological Mechanisms in Winter-over Crew Members, Assessed During Their Stay Using Standardized Touch Stimulation, Computer-based Touch Sensitivity Tests, Questionnaires and Biological Markers.

  Conditions: Social Isolation; Isolated Confined and Extreme Conditions Interventions: Other: No Intervention: Observational Cohort Sponsors: Vrije Universiteit Brussel; Belgium: Belgian Federal Science Policy Office (BELSPO); European Space Agency; Institut Polaire Français Paul-Emile Victor (IPEV) Not yet recruiting

• 3D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological Features

  Conditions: Vestibular Schwannoma Sponsors: Shengjing Hospital Recruiting

• Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms

  Conditions: Neuroendocrine Neoplasm; Gastroenteropancreatic Neuroendocrine Neoplasm Interventions: Drug: Somatostatin Analogue(s) Sponsors: Washington University School of Medicine; Curium US LLC Not yet recruiting

• China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm

  Conditions: Unruptured Intracranial Aneurysms; Pituitary Neuroendocrine Tumor; Craniopharyngioma; Meningioma; Germinoma; Rathke Cleft Cysts; Chordoma; Optic Pathway Glioma; Hypothalamic Neoplasms Interventions: Procedure: Tumor resection followed by aneurysm treatment; Procedure: Aneurysm treatment followed by tumor resection; Other: Observation Sponsors: Cheng sen; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; West China Hospital; Xijing Hospital; Shandong Provincial Hospital; The First Affiliated Hospital of Anhui Medical University; First Affiliated Hospital of Chongqing Medical University; Shengjing Hospital; Lanzhou University Second Hospital; The First Hospital of Jilin University; People's Hospital of Xinjiang Uygur Autonomous Region; Guangdong Provincial Hospital of Traditional Chinese Medicine; Huashan Hospital; Jinling Hospital, China Active, not recruiting

• A Study of Armored CAR T Cells in People With Cancer

  Conditions: Neuroendocrine Cancer; Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ) Interventions: Drug: DLL3-SAVVYZ-IL18 CAR T cell Sponsors: Memorial Sloan Kettering Cancer Center Recruiting

• Effects of Connective Tissue Massage in Patients With Chronic Insomnia

  Conditions: Chronic Insomnia Interventions: Procedure: Connective Tissue Massage; Behavioral: Sleep Hygiene Education Sponsors: Saglik Bilimleri Universitesi Not yet recruiting

• A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

  Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma Interventions: Drug: LBL-024 for Injection; Drug: Etoposide injection; Drug: Cisplatin injection; Drug: Carboplatin injection; Drug: LBL-024 placebo for injection Sponsors: Nanjing Leads Biolabs Co.,Ltd; Peking University Cancer Hospital & Institute Not yet recruiting

• Temporal Interference Transcranial Alternating Current Stimulation for Major Depressive Disorder

  Conditions: Major Depressive Disorder (MDD) Interventions: Device: Temporal Interference transcranial Alternating Current Stimulation (TI-tACS); Device: Sham Temporal Interference transcranial Alternating Current Stimulation (TI-tACS); Device: Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) Sponsors: Central South University; Second Xiangya Hospital of Central South University; Neuropsychiatric Institute of Fuzhou Second General Hospital; Affiliated Wuhan Mental Health Center of Huazhong University of Science and Technology; Affiliated WuTaiShan Hospital of Medical College of Yangzhou University; Xianyue Psychiatric Hospital, Xiamen Not yet recruiting

• Selumetinib for NF2-Related Schwannomatosis

  Conditions: Neurofibromatosis Type 2; NF2; NF2-related Schwannomatosis; Meningioma; Ependymoma; Vestibular Schwannoma Interventions: Drug: Selumetinib Sponsors: Beijing Tiantan Hospital; AstraZeneca Not yet recruiting

• DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  Conditions: Small Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma; Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology; Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology Interventions: Drug: Obrixtamig; Drug: ZL-1310; Drug: Atezolizumab Sponsors: Boehringer Ingelheim; Zai Lab Not yet recruiting

• 211At-MABG in Adults With Advanced Neuroendocrine Cancers

  Conditions: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors; Medullary Thyroid Cancer; Bronchial Carcinoid; Gastroenteropancreatic Neuroendocrine Neoplasm Interventions: Drug: 1 MBq/k of 211At-MABG Fractionated; Drug: 2 MBq/k1 of 211At-MABG Fractionated; Drug: 4 MBq/k of 211At-MABG Fractionated Sponsors: University of Pennsylvania; National Institutes of Health (NIH); National Cancer Institute (NCI) Not yet recruiting

• A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

  Conditions: Gastroenteropancreatic Neuroendocrine Tumor Sponsors: Novartis Pharmaceuticals Recruiting

• Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

  Conditions: Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET); Extra-Pancreatic NET (epNET); Hepatocellular Carcinoma (HCC); Differentiated Thyroid Cancer (DTC); Non-Clear Cell Renal Cell Carcinoma (nccRCC); Colorectal Cancer; Prostate Cancer Interventions: Drug: Cabozantinib; Drug: Zanzalintinib; Drug: Atezolizumab; Drug: Nivolumab; Drug: Abiraterone; Drug: Prednisone; Drug: Enzalutamide Sponsors: Exelixis; Bristol-Myers Squibb Enrolling by invitation

• A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies

  Conditions: Neuroendocrine Tumors, NET; Pheochromocytoma/Paraganglioma; SSTR-expressing Tumors; Medullary Thyroid Carcinoma Interventions: Diagnostic Test: 68Ga-DOTATATE PET/CT; Diagnostic Test: 18F-AmBF3-TATE PET/CT Sponsors: British Columbia Cancer Agency Not yet recruiting

• Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms

  Conditions: Pancreatic Neoplasm; Pancreatic Neuroendocrine Tumor Interventions: Other: Clinical Intervention or Procedure; Other: Electronic Health Record Review; Procedure: Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas; Device: PEF-ablation of pancreatic cyst Sponsors: Ohio State University Comprehensive Cancer Center; Galvanize Therapeutics, Inc. Enrolling by invitation

• STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection

  Conditions: Thyroid Gland Medullary Carcinoma Interventions: Procedure: Biospecimen Collection; Procedure: FDG-Positron Emission Tomography and Computed Tomography Scan; Procedure: Ga-68 PET/CT Scan; Procedure: Neck Dissection; Procedure: Neck Dissection; Behavioral: Surveillance; Procedure: Thyroid Lobectomy; Procedure: Thyroidectomy; Procedure: Ultrasound Imaging Sponsors: Jonsson Comprehensive Cancer Center; Eli Lilly and Company Not yet recruiting

• DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  Conditions: Extrapulmonary Neuroendocrine Cancer (epNEC) Interventions: Drug: Obrixtamig; Drug: Carboplatin; Drug: Etoposide; Device: Ventana DLL3 RxDx assay Sponsors: Boehringer Ingelheim Recruiting

• Breathwork and Stress: Investigating the Mechanisms of Action and Effectiveness of Breathing Interventions in Modulating the Psychophysiological Response to Acute Stress Test

  Conditions: Healthy Adult Participants; Acute Stress Reaction; Stress Biomarkers; Healthy Interventions: Behavioral: Coherent Breathing (6 bpm); Behavioral: Sham Breathing (15 bpm) Sponsors: Medical University of Bialystok Completed

• Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

  Conditions: Recurrent Small Cell Lung Cancer; Extensive-Stage Small Cell Lung Cancer; Small Cell Lung Cancer; Small Cell Lung Carcinoma; Refractory Small Cell Lung Cancer; Extrapulmonary Small Cell Carcinoma; Neuroendocrine Carcinoma; Poorly Differentiated Neuroendocrine Carcinoma; High-Grade Neuroendocrine Carcinoma Interventions: Drug: Autologous B7-H3 CAR T; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: National Cancer Institute (NCI) Recruiting

• Mind-Body Group Interventions for Psychological Distress in Young Breast Cancer Survivors

  Conditions: Breast Cancer Interventions: Behavioral: Breath-Body-Mind (BBM); Behavioral: Survivorship education program (SEP) Sponsors: University of Alabama at Birmingham Recruiting

• Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

  Conditions: Meningioma; Glioblastoma; Acoustic Neuroma; Brain Cancer; Pituitary Adenoma Interventions: Drug: Panitumumab-IRDye800 Sponsors: Eben Rosenthal Recruiting

• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

  Conditions: Small Cell Lung Cancer (SCLC ); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Gastroenteropancreatic NEC (GEP NEC); Neuroendocrine Prostate Cancer (NEPC) Interventions: Biological: ML261 Sponsors: Moonlight Bio, Inc Recruiting

• ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

  Conditions: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage III; Merkel Cell Carcinoma, Stage IV Interventions: Drug: ASTX727 + retifanlimab Sponsors: University of Wisconsin, Madison Not yet recruiting

• Chinese Classics Recitation Training in Subjective Cognitive Decline

  Conditions: Subjective Cognitive Decline (SCD); Subjective Cognitive Decline Interventions: Behavioral: Memory training by Chinese Classics recitation Sponsors: China Medical University Hospital Recruiting

• TheraSphere Japan Pre-Market Study

  Conditions: Liver Neoplasms Interventions: Device: TheraSphere Y-90 glass microsphere Sponsors: Boston Scientific Corporation Recruiting

• Oral and Salivary Biomarkers Associated With Stroke

  Conditions: Stroke Sponsors: University Hospital Center (CHU) of Constantine, Algeria Not yet recruiting

• Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome

  Conditions: Cushing s Syndrome Interventions: Drug: 68Ga-Pentixafor Sponsors: Peking Union Medical College Hospital Recruiting

• Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

  Conditions: Advanced Pheochromocytoma and Paraganglioma; PCPG Interventions: Drug: ONC206; Drug: ONC206: Dose 1; Drug: ONC206: Dose 2 Sponsors: Jazz Pharmaceuticals Recruiting

• Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

  Conditions: Large Cell Neuroendocrine Carcinoma; Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Small Cell Lung Cancer (SCLC); Gastroenteropancreatic NEC (GEP NEC); NEC of the Bladder; Other DLL3 Expressing epNEC Interventions: Drug: [212Pb]Pb-MP0712; Other: [203Pb]Pb-MP0712 Sponsors: Molecular Partners AG; Orano Med LLC Recruiting

• Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

  Conditions: Tumor-associated Hyperinsulinism (Tumor HI) Interventions: Drug: Ersodetug (9 mg/kg) + SOC Sponsors: Rezolute Available

• Stress and Anxiety Effects on Valuation

  Conditions: Reward Value Level Interventions: Behavioral: Socially Evaluated Cold Pressor Task (SECPT); Behavioral: Non-Stressful Control Task Sponsors: NYU Langone Health Recruiting

• Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors

  Conditions: Pheochromocytoma; Cardiovascular Complication; Adrenal Incidentaloma Interventions: Other: adrenalectomy Sponsors: Central Hospital, Nancy, France; Eurocrine Council; European Society of Endocrine Surgery (ESES) Recruiting

• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

  Conditions: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET; Solid Tumor; Somatostatin Receptor Interventions: Drug: RYZ401 Sponsors: RayzeBio, Inc. Recruiting

• A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

  Conditions: SST2-positive Neuroendocrine Neoplasms; Neuroendocrine Tumors; Neuroendocrine Neoplasm Interventions: Drug: CRN09682 Sponsors: Crinetics Pharmaceuticals Inc. Active, not recruiting

• Mapping of Vestibular Centers Activation Using fMRI in Patients With Vestibular Schwannoma

  Conditions: Vestibular Schwannoma; Unilateral Vestibular Deficit; Healthy Interventions: Procedure: vestibular schwannoma resection Sponsors: Marketa Bonaventurova Recruiting